Jesse Labbé: Innovating biotechnology for energy, security and health
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Six science and technology innovators from across the United States will join the fifth cohort of Oak Ridge National Laboratory’s Innovation Crossroads program in June.
Additive manufacturing can make the design and production of specialized tools for geothermal energy cheaper and more efficient, according to a study by Oak Ridge National Laboratory.
As a computer engineer at Oak Ridge National Laboratory, Gina Accawi has long been the quiet and steady force behind some of the Department of Energy’s most widely used online tools and applications.
Oak Ridge National Laboratory researchers, in collaboration with Cincinnati Inc., demonstrated the potential for using multimaterials and recycled composites in large-scale applications by 3D printing a mold that replicated a single facet of a
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
In his career focused on energy storage science, Jianlin Li has learned that discovering new ways to process and assemble batteries is just as important as the development of new materials.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
Oak Ridge National Laboratory scientists proved molybdenum titanium carbide, a refractory metal alloy that can withstand extreme temperature environments, can also be crack free and dense when produced with electron beam powder bed fusion.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.